IMVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunovant Inc (IMVT) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show a bullish trend and hedge funds are increasing their positions, the company's financial performance is weak, with declining net income and EPS. Additionally, insider selling has surged significantly, and there are no recent positive news catalysts or strong signals from Intellectia Proprietary Trading Signals. Analyst ratings are mixed, with some optimism for future programs but no immediate drivers for significant stock movement.
The stock shows a bullish trend with MACD above 0 and positively contracting, RSI in the neutral zone at 65.57, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The current price of $28.91 is above the pivot level of $27.332, with resistance levels at $29.521 and $30.873.
Hedge funds have increased their buying by 133.13% over the last quarter. Analysts see potential in the company's Graves' disease program and other pipeline developments.
Insider selling has increased by 1207.43% in the last month. The company's Phase 3 trial for batoclima in thyroid eye disease failed to meet its primary endpoint, which is a significant setback. No recent news or congress trading data to support positive sentiment.
In Q3 2026, revenue remained at 0 with no YoY growth. Net income dropped to -$110.64M (-0.44% YoY), and EPS declined to -$0.61 (-19.74% YoY). The company has no gross margin or valuation data available.
Analyst ratings are mixed. Goldman Sachs raised its price target to $32 but maintained a Neutral rating. Leerink lowered its target to $50 but remains optimistic about the Graves' disease program. Bernstein initiated coverage with a Market Perform rating and a $28 price target, citing limited news flow this year. Truist and Guggenheim have slightly raised their price targets but remain cautious.
